In many cases of neurogenic bladder patients, bladder compliance is lowered, which is a
factor that deteriorates renal function. It is known that deterioration of renal function is
accompanied in 50 to 70% of patients with low bladder compliance. For patients with poor
bladder compliance, a consensus has not yet been established regarding the treatment method.
This is especially true in the case of drug treatment rather than surgical methods. There are
limited cases where bladder compliance is improved with anticholinergics, which have been
conventionally administered to the patients. According to the existing literature, increase
of bladder compliance was observed in some patients with anticholinergics such as
tolterodine, propiverine, and oxybutynin. But the bladder compliances were not completely
normalized in every patient. Moreover, adverse effects of anticholinergics have been reported
in a significant number of the patients.
The objective of this study is to analyze the effect of mirabegron (a beta3-adrenoceptor
agonist) on bladder compliance in patients who had no effect on bladder compliance with prior
anticholinergics treatment. In this study, low bladder compliance is defined as 20 ml/cmH2O
or less.